Inovio readies clinical trial assessing INO-5401/Tecentriq combo in bladder cancer

|About: Inovio Pharmaceuticals... (INO)|By:, SA News Editor

Inovio Pharmaceuticals (INO +0.4%) and Roche's (OTCQX:RHHBY) Genentech will collaborate on a clinical trial assessing the combination of INO-5401, a T cell-activating immunotherapy, and Tecentriq (atezolizumab) in patients with advanced urothelial carcinoma (bladder cancer).

Inovio will manage the 80-subject open-label study while Genentech will supply product.

Subscribe for full text news in your inbox